Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth.
Using the rat balloon catheter denudation model, we examined the role of transforming growth factor-beta (TGF-beta) isoforms in vascular repair processes. By en face in situ hybridization, proliferating and quiescent smooth muscle cells in denuded vessels expressed high levels of mRNA for TGF-beta1, TGF-beta2, TGF-beta3, and lower levels of TGF-beta receptor II (TGF-betaRII) mRNA. Compared with normal endothelium, TGF-beta1 and TGF-beta2, as well as TGF-betaRII, mRNA were upregulated in endothelium at the wound edge. Injected recombinant soluble TGF-betaRII (TGF-betaR:Fc) localized preferentially to the adventitia and developing neointima in the injured carotid artery, causing a reduction in intimal lesion formation (up to 65%) and an increase in lumen area (up to 88%). The gain in lumen area was largely due to inhibition of negative remodeling, which coincided with reduced adventitial fibrosis and collagen deposition. Four days after injury, TGF-betaR:Fc treatment almost completely inhibited the induction of smooth muscle alpha-actin expression in adventitial cells. In the vessel wall, TGF-betaR:Fc caused a marked reduction in mRNA levels for collagens type I and III. TGF-betaR:Fc had no effect on endothelial proliferation as determined by reendothelialization of the denuded rat aorta. Together, these findings identify the TGF-beta isoforms as major factors mediating adventitial fibrosis and negative remodeling after vascular injury, a major cause of restenosis after angioplasty.
Smith
J D
JD
Center for Molecular Medicine, Maine Medical Center Research Institute, South Portland, ME 04106, USA.
Bryant
S R
SR
Couper
L L
LL
Vary
C P
CP
Gotwals
P J
PJ
Koteliansky
V E
VE
Lindner
V
V
D000199:Actins / Q000378:metabolism; D000800:Angioplasty, Balloon / Q000009:adverse effects; D000818:Animals; D001011:Aorta / Q000166:cytology; D002339:Carotid Arteries / Q000737:chemistry / Q000473:pathology; D020212:Carotid Artery Injuries; D002454:Cell Differentiation / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D003094:Collagen / Q000378:metabolism; D004730:Endothelium, Vascular / Q000737:chemistry / Q000293:injuries* / Q000473:pathology; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism; D005347:Fibroblasts / Q000737:chemistry / Q000166:cytology / Q000201:enzymology; D005355:Fibrosis; D015870:Gene Expression / Q000502:physiology; D006965:Hyperplasia; D017403:In Situ Hybridization; D008024:Ligands; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism*; D012995:Solubility; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism; D017539:Tunica Intima / Q000737:chemistry / Q000166:cytology / Q000201:enzymology
D000199:Actins; D008024:Ligands; D012333:RNA, Messenger; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D003094:Collagen; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II